The value of the global pharmaceutical market is expected to grow by 2.5%-3.5% on a constant-dollar basis in 2009, two percentage points lower than last indicated (Marketletter November 10, 2008), as the deteriorating global economic environment continues to affect market demand, according to the latest report by IMS Health.
The updated forecast predicts global pharmaceutical sales exceeding $750.0 billion for the year, down from the $820.0+ billion previously projected, reflecting both the lower growth rate and currency exchange fluctuations. The sector will feel the impact of the economic climate - but to a lesser extent than many other industries - through 2010, when a rebound is expected. The conclusions are drawn from the latest release of IMS Market Prognosis, a series of strategic market forecasting publications that incorporate updated macroeconomic indicators provided by the Economist Intelligence Unit.
Pharma not "recession-proof"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze